Everything below concerns thymosin alpha 1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Arterial pH < 7.3 (taken by sampling of blood from an artery); or, All three of an international normalized ratio (INR) of greater than 6.5, serum creatinine of greater than 300 micromoles per litre and the presence of encephalopathy (of grade III or IV). These three are markers of coagulopathy, kidney function and mental status.
In the mid-1930s, Pauling, strongly influenced by the biologically oriented funding priorities of the Rockefeller Foundation's Warren Weaver, decided to strike out into new areas of interest. Although Pauling's early interest had focused almost exclusively on inorganic molecular structures, he had occasionally thought about molecules of biological importance, in part because of Caltech's growing strength in biology. Pauling interacted with such great biologists as Thomas Hunt Morgan, Theodosius Dobzhanski, Calvin Bridges and Alfred Sturtevant. His early work in this area included studies of the structure of hemoglobin with his student Charles D. Coryell. He demonstrated that the hemoglobin molecule changes structure when it gains or loses an oxygen molecule. As a result of this observation, he decided to conduct a more thorough study of protein structure in general. He returned to his earlier use of X-ray diffraction analysis. But protein structures were far less amenable to this technique than the crystalline minerals of his former work. The best X-ray pictures of proteins in the 1930s had been made by the British crystallographer William Astbury, but when Pauling tried, in 1937, to account for Astbury's observations quantum mechanically, he could not. It took eleven years for Pauling to explain the problem: his mathematical analysis was correct, but Astbury's pictures were taken in such a way that the protein molecules were tilted from their expected positions.
On December 15, 2020, the acquisition was completed, and Dunkin' Brands ceased to exist as a separate company, with Dunkin', Baskin-Robbins, and the trademark management of Mister Donut, becoming part of Inspire Brands. In May 2026, Dunkin' current parent company Inspire Brands signed a franchise agreement with Montreal-based holding company Foodtastic to bring the restaurant chain back to Canada eight years after the company ceased its operations in the North. Peter Mammas, the president and CEO of restaurant holding company Foodtastic said its return this time will be different, and that this time the chain’s focus will be on Canadian ownership. Mammas expects the first Dunkin’ cafes to open in Canada later this year. A year from now, he says the company will likely be able to open a cafe a week, and about 50 cafes a year. “We have boots on the ground, so we’re going to have local support to support the franchises,” he said. He also said the company will concentrate on opening stores in Quebec and Ontario for the first two years before opening cafes in the Maritimes and the West Coast.
=== National advertising === Kellogg began the breakfast cereal marketing and introduced the first in-box prize in the early 1900s. Quaker Oats entered the market with Puffed Rice and Wheat Berries it had introduced at the 1904 World Fair, with raw grains shot with hot compressed air from tubes, popping up to many times their size. They were marketed as a revolution in food science. In the 1920s, national advertising in magazines and radio broadcasts played a key role in the emergence of the fourth big cereal manufacturer, General Mills. In 1921, James Ford Bell, president of a Minneapolis wheat milling firm, began experimenting with rolled wheat flakes. After tempering, steaming, cracking wheat, and processing it with syrup, sugar, and salt, it was prepared in a pressure cooker for rolling and then dried in an electric oven. By 1925, Wheaties had become the "Breakfast of Champions". In 1928, four milling companies consolidated as the General Mills Company in Minneapolis. The new firm expanded packaged food sales with heavy advertising, including sponsorship of radio programs such as "Skippy", "Jack Armstrong, The All-American Boy", and baseball games. Jack Dempsey, Johnny Weissmuller, and others verified the "Breakfast of Champions" slogan. By 1941 Wheaties had won 12% percent of the cereal market. Experiments with the puffing process produced Kix, a puffed corn cereal, and Cheerios, a puffed oats cereal. Further product innovation and diversification brought total General Mills sales to over $500 million annually (18% in packaged foods) by the early 1950s.
=== Plasma processing === In this technique, paper is first rendered hydrophobic using a hydrophobizing agent such as AKD or fluorocarbon plasma polymerization, and then O2 plasma etching with a mask is used to create hydrophilic patterns in the paper. One benefit of plasma based processes is that the complex designs and functionalities such as fully and semi-enclsoed channels, on-off flow switches, and fluid flow control channels can be incorporated relatively easily. However, cost of production is relatively higher than other fabrication methods.
Sources: en.wikipedia.org
== Additional receptors == Sigma (σ) receptors were once considered to be opioid receptors due to the antitussive actions of many opioid drugs' being mediated via σ receptors, and the first selective σ agonists being derivatives of opioid drugs (e.g., allylnormetazocine). However, σ receptors were found to not be activated by endogenous opioid peptides, and are quite different from the other opioid receptors in both function and gene sequence, so they are now not usually classified with the opioid receptors. The existence of further opioid receptors (or receptor subtypes) has also been suggested because of pharmacological evidence of actions produced by endogenous opioid peptides, but shown not to be mediated through any of the four known opioid receptor subtypes. The existence of receptor subtypes or additional receptors other than the classical opioid receptors (μ, δ, κ) has been based on limited evidence, since only three genes for the three main receptors have been identified. The only one of these additional receptors to have been definitively identified is the zeta (ζ) opioid receptor, which has been shown to be a cellular growth factor modulator with met-enkephalin being the endogenous ligand. This receptor is now most commonly referred to as the opioid growth factor receptor (OGFr).
Official website Alexander Zverev at the Association of Tennis Professionals Alexander Zverev at World Tennis Alexander Zverev at the Davis Cup (archived former page) Alexander Zverev at Olympics.com Alexander Zverev at Team Deutschland (in German) Alexander Zverev on Instagram
In Ukraine the national revival of late 1980s led to the appreciation of Cossack history and culture as symbols of the Ukrainian nation. Cossack symbols and songs were widely used in mass events and demonstrations, particularly during the celebration of the 500th anniversary of the Zaporozhian Sich in 1990. A number of Ukrainian Cossack organizations emerged during that time. Cossacks have taken an active part in many of the conflicts that have taken place since the disintegration of the Soviet Union. These include the War of Transnistria, Georgian–Abkhazian conflict, Georgian–Ossetian conflict, First Nagorno-Karabakh War, 2016 Nagorno-Karabakh war, First Chechen War, Second Chechen War, and the 2014 pro-Russian unrest in Ukraine and both the subsequent War in Donbas and the 2022 Russian invasion of Ukraine.
The generation of reducing equivalents, in the form of NADPH, used in reductive biosynthesis reactions within cells (e.g. fatty acid synthesis). Production of ribose 5-phosphate (R5P), used in the synthesis of nucleotides and nucleic acids. Production of erythrose 4-phosphate (E4P), used in the synthesis of aromatic amino acids in non-mammals. Aromatic amino acids, in turn, are precursors for many biosynthetic pathways, including the lignin in wood. Dietary pentose sugars derived from the digestion of nucleic acids may be metabolized through the pentose phosphate pathway, and the carbon skeletons of dietary carbohydrates may be converted into glycolytic/gluconeogenic intermediates. In mammals, the PPP occurs exclusively in the cytoplasm. In humans, it is found to be most active in the liver, mammary glands, and adrenal cortex. The PPP is one of the three main ways the body creates molecules with reducing power, accounting for approximately 60% of NADPH production in humans. One of the uses of NADPH in the cell is to prevent oxidative stress. It reduces glutathione via glutathione reductase, which converts reactive H2O2 into H2O by glutathione peroxidase. If absent, the H2O2 would be converted to hydroxyl free radicals by Fenton chemistry, which can attack the cell. Erythrocytes, for example, generate a large amount of NADPH through the pentose phosphate pathway to use in the reduction of glutathione. Hydrogen peroxide is also generated for phagocytes in a process often referred to as a respiratory burst.
THC, referred to as dronabinol in the pharmaceutical context, is approved in the United States as a capsule or solution to relieve chemotherapy-induced nausea and vomiting and HIV/AIDS-induced anorexia. THC is an active ingredient in nabiximols (Sativex), a specific extract of Cannabis that was approved as a botanical drug in the United Kingdom in 2010 as a mouth spray for people with multiple sclerosis to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms. Nabiximols (as Sativex) is available as a prescription drug in Canada. In 2021, nabiximols was approved for medical use in Ukraine. THC is sometimes prescribed off-label to treat glaucoma, Crohn's disease, and post-traumatic stress disorder (PTSD).
Sources: en.wikipedia.org
=== Takeshita === The Takeshita geometry consists of a 54.43° electric sector, and short drift length, a second electric sector of the same curvature direction followed by another drift length before a 180° magnetic sector of opposite curvature direction.
Food packaging is a packaging system specifically designed for food and represents one of the most important aspects among the processes involved in the food industry, as it provides protection from chemical, biological and physical alterations. The main goal of food packaging is to provide a practical means of protecting and delivering food goods at a reasonable cost, while meeting the needs and expectations of both consumers and industries. Additionally, current trends like sustainability, environmental impact reduction, and shelf-life extension have gradually become some of the most important aspects in designing a packaging system.
Beriplast P Combi-Set, fibrin sealant kit, freeze-dried fibrin sealant for topical application Fibrogammin P, freeze-dried human coagulation factor XIII concentrate TachoComb, fibrin sealant fleece-type, fleece-type collagen preparations coated with fibrin glue components Product availability varies from country to country, depending on registration status.
The African Renaissance is the concept that the African people shall overcome the current challenges confronting the continent and achieve cultural, scientific, and economic renewal. This concept was first articulated by Cheikh Anta Diop in a series of essays between 1946 and 1960, later collected in a book titled Towards the African Renaissance. Diop's ideas were further popularized by former President of South Africa Thabo Mbeki during his tenure as Deputy President, where the African Renaissance continues to play a key role in the post-apartheid intellectual agenda.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.